Clinical Trial Update: Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating mesenchymal stem cells for cisplatin-induced acute kidney injury in patients with solid tumors; the study status is withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Solid Tumors

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Solid Tumors, Acute Kidney Injury | Phase 1 | Status: WITHDRAWN